Clinical Trial Update: Clinical Study of Universal CD19 CAR-γδT Cell Injection in the Treatment of Adult Relapsed/Refractory B-cell Lymphoma [Phase 1]

View source ↗

Summary

This clinical trial update describes a Phase 1 study evaluating universal CD19 CAR-γδT cell injections for adults with relapsed or refractory B-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma

Drugs mentioned

• Universal CD19 CAR-γδT cell therapy

Snippet

Sponsor: The Second Affiliated Hospital of Fujian Medical University | Conditions: Recurrent/Refractory B-cell Lymphoma | Phase 1 | Status: NOT_YET_RECRUITING